pubmed.ncbi.nlm.nih.gov

Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC-MS - PubMed

Analysis of 25 C NBOMe in Seized Blotters by HPTLC and GC-MS

Boris Duffau et al. J Chromatogr Sci. 2016 Aug.

Abstract

Use of unauthorized synthetic drugs is a serious, forensic, regulatory and public health issue. In this scenario, consumption of drug-impregnated blotters is very frequent. For decades, blotters have been generally impregnated with the potent hallucinogen known as lysergic acid diethylamide (LSD); however, since 2013 blotter stamps with N-2 methoxybenzyl-substituted phenylethylamine hallucinogen designated as "NBOMes" have been seized in Chile. To address this issue with readily accessible laboratory equipment, we have developed and validated a new HPTLC method for the identification and quantitation of 25-C-NBOMe in seized blotters and its confirmation by GC-MS. The proposed method was validated according to SWGTOX recommendations and is suitable for routine analysis of seized blotters containing 25-C-NBOMe. With the validated method, we analyzed 15 real samples, in all cases finding 25-C-NBOMe in a wide dosage range (701.0-1943.5 µg per blotter). In this situation, we can assume that NBOMes are replacing LSD as the main hallucinogenic drug consumed in blotters in Chile.

© The Author 2016. Published by Oxford University Press.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.

Structure of 25-C-NBOMe.

Figure 2.
Figure 2.

TIC and mass spectrum of standard of 25-C-NBOMe. This figure is available in black and white in print and in color at JCS online.

Figure 3.
Figure 3.

Results of purity and spectrum comparison of real samples and reference material of 25-C-NBOMe. This figure is available in black and white in print and in color at JCS online.

Figure 4.
Figure 4.

Densitogram with 25-C-NBOMe, LSD and DMT as an example of selectivity and separation capability of the proposed method. This figure is available in black and white in print and in color at JCS online.

Figure 5.
Figure 5.

The calibration plot.

Similar articles

Cited by

References

    1. Casale J.F., Hays P.A.; Characterization of eleven 2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) derivatives and differentiation from their 3- and 4-methoxybenzyl analogues—part I; Microgram Journal, (2012); 9: 84–109.
    1. Bersani F.S., Corazza O., Albano G., Valeriani G., Santacroce R., Bolzan F. et al. ; 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug; BioMed Research International, (2014); 2014: 1–6. - PMC - PubMed
    1. Zuba D., Sekuła K., Buczek A.; 25C-NBOMe—new potent hallucinogenic substance identified on the drug market; Forensic Science International, (2013); 227: 7–14. - PubMed
    1. Lawn W., Barratt M., Williams M., Horne A., Winstock A.; The NBOMe hallucinogenic drug series: patterns of use, characteristics of users and self-reported effects in a large international sample; Journal of Psychopharmacology, (2014); 28: 780–788. http://www.ncbi.nlm.nih.gov/pubmed/24569095?dopt=Abstract. - PubMed
    1. Braden M.R., Parrish J.C., Naylor J.C., Nichols D.E.; Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists; Molecular Pharmacology, (2006); 70: 1956–1964. - PubMed

Publication types

MeSH terms

Substances